Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
Charles River supports preclinical research — laboratory animals, disease models and drug safety testing.
Before a drug reaches humans it is tested for safety, and the regulator requires specific procedures. The company supplies the research animals, the laboratories and the specialists — a stage a developer finds cheaper to outsource than to maintain.
Demand depends on how many programmes the industry is starting, and that in turn on the availability of money at biotech start-ups and on large pharmaceutical budgets. A separate factor is regulators gradually accepting alternative methods in place of animal testing. Risks: shrinking research budgets and ethical pressure. The company pays no dividend.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Charles River Laboratories International, Inc. (CRL) is a company in the Health care sector; its shares trade on NYSE.
The price of Charles River Laboratories International, Inc. (CRL) on November 2, 2026 is 347.84 $, −3.22 % on the day. Over the past year the price changed by +79.38 %. Market capitalization is 16.98 billion $, rank 4 among 10 stocks of the same industry with a known capitalization.
Charles River Laboratories International, Inc. trades on NYSE under the ticker CRL. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks CRL has traded between 146.20 $ and 333.30 $. As of 2 November 2026 the price stood 85.54 % of the way from the 52-week low to the high.
Over one year CRL shares rose 79.38 %; over six months they rose 73.08 %. Volatility over 90 days is 40.16 %. Dividends are not included: this is price change only, as of 2 November 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 4.2, above the sector median of 3.6. Price to book is 6.0, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Charles River Laboratories International, Inc. reported revenue of 4.0B $ and a net loss of 238M $ over the last four quarters. Net margin is −5.96 %. Revenue changed by −0.74 % year over year. Earnings per share are −4.80 $. Market capitalisation is 17.0B $.
CRL has a return on equity of −8.40 %, above the sector median of −40.58 %. Return on assets is −3.17 %, above the sector median of −30.08 %. Operating margin is 2.25 %, above the sector median of −20.96 %.